BioSpace

BioSpace Your source for biopharma news and jobs

Novo Nordisk's GLP-1s outsell Eli Lilly and Company's thanks to its superior marketing. Here’s how.
03/01/2025

Novo Nordisk's GLP-1s outsell Eli Lilly and Company's thanks to its superior marketing. Here’s how.


Novo Nordisk’s GLP-1s outsell Eli Lilly’s thanks to its superior marketing. Here’s how.

Eli Lilly and Company's request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief...
03/01/2025

Eli Lilly and Company's request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.


Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its interests.

Job postings in California took a dip in December during the holiday period, but activity is expected to pick up in Janu...
02/01/2025

Job postings in California took a dip in December during the holiday period, but activity is expected to pick up in January. Companies including Amgen, Gilead Sciences and Eli Lilly and Company are hiring.

Job postings in California took a dip in December during the holiday period, but activity is expected to pick up in January.

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D profes...
02/01/2025

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D professionals in those areas. A biotech talent acquisition expert at Harbinger Health shares his insights on these in-demand roles.

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D professionals in those areas. A biotech talent acquisition expert shares his insights on these in-demand roles.

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the indust...
02/01/2025

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.


In this episode of Denatured, BioSpace's Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA appr...
02/01/2025

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval in the second half of 2025.


With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval in the second half of 2025.

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing d...
02/01/2025

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal with Innovent for $1 billion in biobucks.


Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal with Innovent for $1 billion in biobucks.

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck's Winrevair and the ...
02/01/2025

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck's Winrevair and the FDA’s greenlight for an injectable formulation of Bristol Myers Squibb's cancer blockbuster.


Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
02/01/2025

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.


In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone paymen...
02/01/2025

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.


Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 bil...
23/12/2024

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic.


The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion in 2023. It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic.

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity...
23/12/2024

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.


The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in combination with diet and exercise.

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate...
23/12/2024

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk, Pitchbook said in its 2025 outlook.


High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk, Pitchbook said in its 2025 outlook.

Novo Nordisk’s Alhemo has received the regulator’s greenlight for preventing bleeding episodes or reducing their frequen...
23/12/2024

Novo Nordisk’s Alhemo has received the regulator’s greenlight for preventing bleeding episodes or reducing their frequency in adults and children aged 12 and up with hemophilia A or B who have developed inhibitors, which are antibodies that neutralize clotting factors such as factor VIII or factor IX.

In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.

Following a 90% drop in share price due to an FDA rejection and a warning letter over Applied Therapeutics’ conduct duri...
23/12/2024

Following a 90% drop in share price due to an FDA rejection and a warning letter over Applied Therapeutics’ conduct during a clinical trial, the biotech’s CEO has stepped aside.


Following a 90% drop in share price due to an FDA rejection and a warning letter over Applied Therapeutics’ conduct during a clinical trial, the biotech’s CEO has stepped aside.

Javara, a North Carolina–based clinical research organization, is laying off staff as the company restructures. Details ...
23/12/2024

Javara, a North Carolina–based clinical research organization, is laying off staff as the company restructures. Details about the number of employees being let go was not reported.


Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in ...
23/12/2024

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric low-grade glioma. Geron Corporation and ImmunityBio also notched wins.


Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric low-grade glioma. Geron Corporation and ImmunityBio also notched wins.

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and...
23/12/2024

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and Company and AbbVie, following the predictable pattern of successes and failures that characterizes this space.


This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that characterizes this space.

Address


Telephone

+18772777585

Website

Alerts

Be the first to know and let us send you an email when BioSpace posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to BioSpace:

Shortcuts

  • Address
  • Telephone
  • Alerts
  • Contact The Business
  • Claim ownership or report listing

  • Want your business to be the top-listed Media Company?

Share